Luc Bauchet1,2,3, Jacques Guyotat4, Thiébaud Picart5,6,7, David Meyronet8,9,10, Johan Pallud11,12,13, Chloé Dumot4,8,14, Philippe Metellus15,16, Sonia Zouaoui1,2, Moncef Berhouma4,8,17, François Ducray8,9,18. 1. Department of Neurosurgery, Montpellier University Hospital, Montpellier, France. 2. FBTDB (French Brain Tumor DataBase), Montpellier University Hospital, Montpellier, France. 3. Institut Des Neurosciences de Montpellier, INSERM U1051, Hôpital Saint Eloi, Montpellier, France. 4. Department of Neurosurgery, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, 59 Boulevard Pinel, 69667, Bron, France. 5. Department of Neurosurgery, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, 59 Boulevard Pinel, 69667, Bron, France. thiebaud.picart@chu-lyon.fr. 6. Claude Bernard University Lyon 1, Lyon, France. thiebaud.picart@chu-lyon.fr. 7. Department of Cancer Cell Plasticity, INSERM U1052, Cancer Research Center of Lyon, Lyon, France. thiebaud.picart@chu-lyon.fr. 8. Claude Bernard University Lyon 1, Lyon, France. 9. Department of Cancer Cell Plasticity, INSERM U1052, Cancer Research Center of Lyon, Lyon, France. 10. Groupe Hospitalier Est, Department of Neuropathology, Hospices Civils de Lyon, Bron, France. 11. Department of Neurosurgery, Hôpital Sainte-Anne, Paris, France. 12. Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 13. IMA-Brain, INSERM U894, Institut de Psychiatrie et Neurosciences de Paris, Paris, France. 14. CarMeN Laboratory, Inserm U1060, INRA U1397, INSA Lyon, Université Claude Bernard Lyon 1, Lyon, France. 15. Hôpital Privé Clairval, Ramsay Général de Santé, Marseille, France. 16. Institut de Neurophysiopathologie, UMR 7051, Université D'Aix-Marseille, Marseille, France. 17. CREATIS Laboratory, Inserm U1206, UMR 5220, Université de Lyon, Villeurbanne, France. 18. Department of Neurooncology, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Bron, France.
Abstract
PURPOSE: To analyze the outcomes and predictors in a large series of cerebellar glioblastomas in order to guide patient management. METHODS: The French brain tumor database and the Club de Neuro-Oncologie of the Société Française de Neurochirurgie retrospectively identified adult patients with cerebellar glioblastoma diagnosed between 2003 and 2017. Diagnosis was confirmed by a centralized neuropathological review. RESULTS: Data from 118 cerebellar glioblastoma patients were analyzed (mean age 55.9 years, 55.1% males). The clinical presentation associated raised intracranial pressure (50.8%), static cerebellar syndrome (68.6%), kinetic cerebellar syndrome (49.2%) and/or cranial nerve disorders (17.8%). Glioblastomas were hemispheric (55.9%), vermian (14.4%) or both (29.7%). Hydrocephalus was present in 49 patients (41.5%). Histologically, tumors corresponded either to IDH-wild-type or to K27-mutant glioblastomas. Surgery consisted of total (12.7%), subtotal (35.6%), partial resection (33.9%) or biopsy (17.8%). The postoperative Karnofsky performance status was improved, stable and worsened in 22.4%, 43.9% and 33.7% of patients, respectively. Progression-free and overall survivals reached 5.1 months and 9.1 months, respectively. Compared to other surgical strategies, total or subtotal resection improved the Karnofsky performance status (33.3% vs 12.5%, p < 0.001), prolonged progression-free and overall survivals (6.5 vs 4.3 months, p = 0.015 and 16.7 vs 6.2 months, p < 0.001, respectively) and had a comparable complication rate (40.4% vs 31.1%, p = 0.29). After total or subtotal resection, the functional outcomes were correlated with age (p = 0.004) and cerebellar hemispheric tumor location (p < 0.001) but not brainstem infiltration (p = 0.16). CONCLUSION: In selected patients, maximal resection of cerebellar glioblastoma is associated with improved onco-functional outcomes, compared with less invasive procedures.
PURPOSE: To analyze the outcomes and predictors in a large series of cerebellar glioblastomas in order to guide patient management. METHODS: The French brain tumor database and the Club de Neuro-Oncologie of the Société Française de Neurochirurgie retrospectively identified adult patients with cerebellar glioblastoma diagnosed between 2003 and 2017. Diagnosis was confirmed by a centralized neuropathological review. RESULTS: Data from 118 cerebellar glioblastomapatients were analyzed (mean age 55.9 years, 55.1% males). The clinical presentation associated raised intracranial pressure (50.8%), static cerebellar syndrome (68.6%), kinetic cerebellar syndrome (49.2%) and/or cranial nerve disorders (17.8%). Glioblastomas were hemispheric (55.9%), vermian (14.4%) or both (29.7%). Hydrocephalus was present in 49 patients (41.5%). Histologically, tumors corresponded either to IDH-wild-type or to K27-mutant glioblastomas. Surgery consisted of total (12.7%), subtotal (35.6%), partial resection (33.9%) or biopsy (17.8%). The postoperative Karnofsky performance status was improved, stable and worsened in 22.4%, 43.9% and 33.7% of patients, respectively. Progression-free and overall survivals reached 5.1 months and 9.1 months, respectively. Compared to other surgical strategies, total or subtotal resection improved the Karnofsky performance status (33.3% vs 12.5%, p < 0.001), prolonged progression-free and overall survivals (6.5 vs 4.3 months, p = 0.015 and 16.7 vs 6.2 months, p < 0.001, respectively) and had a comparable complication rate (40.4% vs 31.1%, p = 0.29). After total or subtotal resection, the functional outcomes were correlated with age (p = 0.004) and cerebellar hemispheric tumor location (p < 0.001) but not brainstem infiltration (p = 0.16). CONCLUSION: In selected patients, maximal resection of cerebellar glioblastoma is associated with improved onco-functional outcomes, compared with less invasive procedures.
Authors: Ranjith Babu; Richa Sharma; Isaac O Karikari; Timothy R Owens; Allan H Friedman; Cory Adamson Journal: J Clin Neurosci Date: 2013-05-22 Impact factor: 1.961
Authors: Hadie Adams; Kaisorn L Chaichana; Javier Avendaño; Brian Liu; Shaan M Raza; Alfredo Quiñones-Hinojosa Journal: World Neurosurg Date: 2013-02-06 Impact factor: 2.104
Authors: Hee Jin Cho; Junfei Zhao; Sang Won Jung; Erik Ladewig; Doo-Sik Kong; Yeon-Lim Suh; Yeri Lee; Donggeon Kim; Sun Hee Ahn; Mykola Bordyuh; Hyun Ju Kang; Jason K Sa; Yun Jee Seo; Sung Tae Kim; Do Hoon Lim; Yun-Sik Dho; Jung-Il Lee; Ho Jun Seol; Jung Won Choi; Woong-Yang Park; Chul-Kee Park; Raul Rabadan; Do-Hyun Nam Journal: Neuro Oncol Date: 2019-01-01 Impact factor: 12.300